Document is current
Any future updates will be listed below
-
Authors
Willoch-Allen, Katarina
Zhao, Zhi
Ayuda-Durán, Pilar
Mikaeloff, Flora
Struyf, Nona
Österroos, Albin
Lehmann, Sören
Kallioniemi, Olli
Saarela, Jani
Tyner, Jeffrey W.
Erkers, Tom
Enserink, Jorrit M.
Aittokallio, Tero
- License Information
-
More Information
Article History
Received: 4 July 2025
Accepted: 4 May 2026
First Online: 14 May 2026
Competing interests
: Author J.W.T. is an Associate Editor of npj Precision Oncology. J.W.T. was not involved in the journal’s review of, or decisions related to, this manuscript. The authors declare the following competing financial interests: O.K. is a co-founder and a board member of Sartar Therapeutics and acts as a scientific advisor to the Knut and Alice Wallenberg Foundation as well as the Novo Nordisk Foundation (all unrelated to the topics of this study). J.W.T. received research support from Acerta, Agios, Aptose, Array, AstraZeneca, Constellation, Genentech, Gilead, Incyte, Janssen, Kronos, Meryx, Petra, Schrodinger, Seattle Genetics, Syros, Takeda, and Tolero and serves on the advisory board for Recludix Pharm, AmMax Bio, and Ellipses Pharma. T.A. has received unrelated research funding from Mobius Biotechnology GmbH. The rest of the authors declare no Competing Financial or Non-Financial Interests.
